Logo

American Heart Association

  148
  0


Final ID:

New and Emerging Targets for Lowering LDL-Cholesterol and Triglycerides: ANGPTL3, CETP, APOC-III

  • Kastelein, John  ( ACADEMIC MEDICAL CENTER , Amsterdam , Netherlands )
  • Ray, Kausik  ( IMPERIAL COLLEGE LONDON , London , United Kingdom )
  • Author Disclosures:
    John Kastelein: DO have relevant financial relationships ; Employee:NewAmsterdam Pharma:Active (exists now) | Kausik Ray: DO have relevant financial relationships ; Research Funding (PI or named investigator):sanofi, daiichi sankyo, ultragenix, amarin:Active (exists now) ; Individual Stocks/Stock Options:New Amsteram Pharma, Scribe, Pemi31:Active (exists now) ; Speaker:Novartis, Daiichi, Merck, AZ, Novo Nordisk, BI, Sanofi, Amgen,:Active (exists now) ; Consultant:Kowa, Bayer,:Past (completed) ; Consultant:novartis, daiichi sankyo, AZ, MSD, Esoerion, Scribe, Silence Therapeutics, Cleerly, Nodthera, New Amsterdam Pharma, Amgen, Sanofi, Novo Nordisk, AZ,:Active (exists now) ; Research Funding (PI or named investigator):amgen:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Annual Lipid Updates - 2024

Sunday, 11/17/2024 , 08:00AM - 09:15AM

Cardiovascular Seminar

More abstracts on this topic:
Lipoprotein(a): Modifiable Risk Factor, Update in Targeted Therapies

Yeang Calvin, Bhatia Harpreet, Mehta Anurag

New Frontiers in Triglyceride Lowering

Tokgozoglu Lale, Remaley Alan T, Cariou Bertrand, Hudgins Lisa

You have to be authorized to contact abstract author. Please, Login
Not Available